Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, has announced a research collaboration with Eli Lilly and Company to develop genetic medicine therapeutics.
The collaboration builds on a successful pilot between the two companies and will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas. The central role of RNA in orchestrating essential biological processes holds significant potential to address critical diseases that traditional drugs have not been able to target effectively. Historically, drugging RNA has presented tremendous challenges. Genetic Leap’s proprietary AI platform is revolutionising the approach to drugging RNA.
“We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines,” said Dr Bertrand Adanve, CEO and Founder of Genetic Leap. “Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal.”
Under the terms of the agreement, Genetic Leap will receive from Lilly up to US$409 million in upfront, development, clinical, regulatory and commercial milestone payments, in addition to tiered royalties.